Summer Sun Safety Month: How to Stay Healthy While Enjoying the Sun With Tristan Knight, MD, FRCPC, and Matthew Hadfield, DO

This August is Summer Sun Safety Month, a time to shed light on the importance of protection from sun damage and best practices for limiting exposure while still enjoying the outdoors. In this interview, Editorial Board members Dr. Tristan Knight and Dr. Matthew Hadfield delve into:

An overview of the science and background related to the sun and ultraviolet (UV) rays
Types of damage that can be caused by sunburn and overexposure to the sun
Measures to reduce the risk of sun damage and promote sun safety for both children and adults
An explanation of SPF and different types of sunscreens
Common questions from patients and parents and tips to maximize sun safety
The ABCs of melanoma—asymmetry, border, and color—and what to do if you notice a change in your skin
And more!

About Dr. Knight and Dr. Hadfield

Tristan E. Knight, MD, FRCPC, is a Clinical Assistant Professor of Pediatrics at the University of Washington (Seattle, WA) and practices at Seattle Children’s Hospital. He completed his Pediatric Residency at the University of Hawaii, a Pediatric Hematology/Oncology Fellowship at the Children’s Hospital of Michigan, and a Bone Marrow Transplant (BMT)/Cellular Therapy Fellowship at the Hospital for Sick Children (SickKids). His clinical areas of interest are allogeneic/autologous BMT and cellular/immune effector cell therapy, particularly in the treatment of children with ALL, AML, and neuroblastoma. He has published extensively on novel therapeutic approaches in these conditions, including the use of CAR T-cell therapy in children.

Matthew Hadfield, DO, is a Medical Oncologist at Brown University/Legorreta Cancer Center, with a pending faculty appointment at the Warren Alpert School of Medicine of Brown University. He recently completed his Hematology/Oncology Fellowship at Brown University. Dr. Hadfield’s clinical and research interests are in phase 1 clinical trials and developmental therapeutics, as well as cutaneous malignancies and immunotherapy-related adverse events.